|Articles|December 1, 2001
CMS expands coverage for verteporfin therapy
New York-The Centers for Medicare and Medicaid Services (CMS)-formerlythe Health Care Financing Administration-will begin reimbursing patientswho use verteporfin for injection (Visudyne) with occult choroidal neovascularization(CNV) lesions secondary to age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Rayner’s RayOne EMV Toric intraocular lens
2
Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA
3
NeuroOp Guru: When proptosis isn’t thyroid eye disease
4
Ophthalmic innovation by the decades: The 1980s and 1990s
5